【摘 要】
：
Background: Natural killer (NK) cells are critical effectors in the immune response against malignancy and infection, and microRNAs (miRNAs) play important roles in NK cell biology.However, the microR
【机 构】
：
Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease,School of
论文部分内容阅读
Background: Natural killer (NK) cells are critical effectors in the immune response against malignancy and infection, and microRNAs (miRNAs) play important roles in NK cell biology.However, the microRNA transcriptomes of the different phenotypes and functions of human NK cell subsets are incompletely understood.
其他文献
Although rabies can be effectively prevented after recognized exposures, there is no established effective therapy for human rabies.The Milwaukee protocol, consisting of therapeutic coma, ketamine, ri
Scalable, high quality cell manufacturing is key to providing safe, effective and economically viable cell therapies.In the case of autologous T-cell therapies this entails, high density expansion of
Oncolytic viruses have been utilized for the treatment of various cancers.However, delivery of the viral particles to tumor cells remains a major challenge.Microparticles (MPs) are vesicle forms of pl
肿瘤治疗性疫苗多数临床研究疗效有限.美国FDA批准上市的前列腺癌DC疫苗Provenge,其生存期与对照组相比提高了4.1个月,虽然有效,但距离人们的期望值尚远.人们也期望应用肿瘤干细胞样疫苗获取更好的疗效.
Background and purpose: It was a fact that Igs was overexpressed in many non B cell-derived cancer cells, moreover, its function, at least, the IgG was found to be directly involved in carcinogenesis.
For a robust and universal oncolytic adenoviral cancer treatment, we have constructed a promoter library consisting of Hsp-70 promoter and a combination of the trimeric cis-elements, which are shared
CHK抑制剂是一种DNA损伤治疗的有效药物。近来，组蛋白去乙酰化酶抑制剂显示对几种癌症有效，包括非霍奇金淋巴瘤。为了评估上述两种小分子抑制剂联合应用对人淋巴瘤的治疗效果，我们通过体内和体外实验评价了AR42(组蛋白去乙酰化酶抑制剂)和CHK Ⅱ抑制剂联合治疗的效果。
背景：许多研究显示miR-21在结直肠癌(CRC)中显著升高，认为是一个致癌miRNA.miR-21在肿瘤细胞的生物学行为如生长、增殖、代谢、血管生成、侵袭、化疗耐药中发挥重要作用.目的：研究miR-21过表达对结肠癌HCT-116细胞生物学行为和对5-Fu和西妥昔单抗cetuximab敏感性的影响，并探索其可能机制.
肝细胞癌(hepatocellularcarcinoma,HCC)是严重威胁着人类生命的恶性肿瘤.目前,临床用于HCC治疗的靶向药物仅有索拉菲尼(sorafenib)一种,不仅由于肝癌的个体差异性较大,其临床有效率也仅有25％,且费用昂贵.因此,如何发现新型的HCC靶向治疗药物,对于控制肝癌发展、延长患者生存期具有重要的应用价值.
Backgroud: Immune cells are believed to participate in initiating anti-tumor effects during regular tumor therapy such as cytokine injection, radiation, hyperthermia and chemotherapy.